Table 3.

Demographic and clinical characteristics of patients prescribed CSs since 2014 [Objective B]

Duration of CSs		Long-term use [≥180 days]	Non-long-term use [<180 days]
Number of patients prescribed CSs, n		590	640
Duration of CS use, days, median [IQR]		365.0 [294.0, 365.0]	72.0 [41.8, 117.3]
Sex	Male, n [%]	368 [62.4]	387 [60.5]
	Female, n [%]	222 [37.6]	253 [39.5]
Age, years	<20, n [%]	42 [7.1]a	61 [9.5]b
	≥20, <40, n [%]	195 [33.1]	257 [40.2]
	≥40, <60, n [%]	297 [50.3]	285 [44.5]
	≥60, n [%]	56 [9.5]	37 [5.8]
CS dosec, mg/day, median [IQR]		8.1 [5.0, 11.5]	14.7 [10.0, 18.9]
Initial CS dose, mg/day	<10, n [%]	190 [32.2]	70 [10.9]
	≥10, <20, n [%]	139 [23.6]	132 [20.6]
	≥20, <30, n [%]	107 [18.1]	153 [23.9]
	≥30, n [%]	154 [26.1]	285 [44.5]
With re-administration of CSs, n [%]		180 [30.5]	209 [32.7]
Thiopurine non-user, n [%]		374 [63.4]	487 [76.1]
Biologics non-user, n [%]		475 [80.5]	559 [87.3]
Infliximab non-user, n [%]		523 [88.6]	595 [93.0]
Adalimumab non-user, n [%]		537 [91.0]	604 [94.4]
Golimumab non-user, n [%]		585 [99.2]	640 [100.0]
Medical institution visited on the index date, n [%]
University hospital		102 [17.3]	109 [17.0]
National/public hospital		111 [18.8]	81 [12.7]
Clinic [<20 beds]		152 [25.8]	184 [28.8]
Other hospitald		225 [38.1]	266 [41.6]

Abbreviations: CS, corticosteroid; IQR, interquartile range.

^aSeventeen [2.9%] patients were aged <16 years.

^bTwenty-two [3.4%] patients were aged <16 years.

^cCS dose throughout the follow up period.

^dHospital with ≥20 beds other than a university hospital or national/public hospital.